Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 3 | 5 |
| 1995 | 3 | 6 | 9 |
| 1996 | 8 | 9 | 17 |
| 1997 | 4 | 8 | 12 |
| 1998 | 0 | 7 | 7 |
| 1999 | 6 | 4 | 10 |
| 2000 | 5 | 13 | 18 |
| 2001 | 3 | 10 | 13 |
| 2002 | 4 | 4 | 8 |
| 2003 | 9 | 9 | 18 |
| 2004 | 10 | 11 | 21 |
| 2005 | 6 | 14 | 20 |
| 2006 | 17 | 11 | 28 |
| 2007 | 13 | 14 | 27 |
| 2008 | 8 | 17 | 25 |
| 2009 | 15 | 13 | 28 |
| 2010 | 19 | 20 | 39 |
| 2011 | 14 | 8 | 22 |
| 2012 | 15 | 12 | 27 |
| 2013 | 20 | 19 | 39 |
| 2014 | 19 | 17 | 36 |
| 2015 | 23 | 18 | 41 |
| 2016 | 27 | 14 | 41 |
| 2017 | 27 | 8 | 35 |
| 2018 | 19 | 21 | 40 |
| 2019 | 30 | 23 | 53 |
| 2020 | 22 | 30 | 52 |
| 2021 | 21 | 21 | 42 |
| 2022 | 6 | 42 | 48 |
| 2023 | 0 | 38 | 38 |
| 2024 | 4 | 15 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). Int J Gynecol Cancer. 2024 Aug 05; 34(8):1140-1148.
-
Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence? Cells. 2024 Jul 30; 13(15).
-
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 Jul 09; 8(13):3507-3518.
-
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e433330.
-
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. 2024 05 28; 331(20):1714-1721.
-
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 May; 8:e2300531.
-
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 Apr 25; 143(17):1713-1725.
-
Uterine Inflammatory Myofibroblastic Tumors: p16 as a Surrogate for CDKN2A Deletion and Predictor of Aggressive Behavior. Am J Surg Pathol. 2024 Jul 01; 48(7):813-824.
-
Using optical coherence tomography to optimize Mohs micrographic surgery. Sci Rep. 2024 04 17; 14(1):8900.
-
Natural history of undifferentiated pleomorphic sarcoma: Experience from the US Sarcoma Collaborative. J Surg Oncol. 2024 Jun; 129(7):1354-1363.